Filing Details
- Accession Number:
- 0001209191-19-025793
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-04-24 18:11:50
- Reporting Period:
- 2019-04-22
- Accepted Time:
- 2019-04-24 18:11:50
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1595893 | Turning Point Therapeutics Inc. | TPTX | Pharmaceutical Preparations (2834) | 463826166 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1767584 | Hongbo Lu | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 225 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-04-22 | 1,120,730 | $0.00 | 1,120,730 | No | 4 | C | Indirect | By LAV Prime Limited |
| Common Stock | Acquisiton | 2019-04-22 | 546,820 | $0.00 | 1,667,550 | No | 4 | C | Indirect | By LAV Prime Limited |
| Common Stock | Acquisiton | 2019-04-22 | 60,000 | $18.00 | 1,727,550 | No | 4 | P | Indirect | By LAV Prime Limited |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | By LAV Prime Limited |
| No | 4 | C | Indirect | By LAV Prime Limited |
| No | 4 | P | Indirect | By LAV Prime Limited |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Acquisiton | 2019-04-22 | 15,000 | $0.00 | 15,000 | $27.06 |
| Common Stock | Series C Preferred Stock | Disposition | 2019-04-22 | 4,314,809 | $0.00 | 1,120,730 | $0.00 |
| Common Stock | Series D Preferred Stock | Disposition | 2019-04-22 | 2,105,259 | $0.00 | 546,820 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 15,000 | 2029-04-21 | No | 4 | A | Direct | |
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Automatic conversion, in connection with the Issuer's initial public offering, of each share of preferred stock into 0.25974026 shares of common stock. The shares have no expiration date.
- The Reporting Person is a Partner at Lilly Asia Ventures and may be deemed to beneficially own the shares held by LAV Prime Limited.
- The shares were purchased at the Issuer's initial public offering.
- The option will become fully vested on the date of the Issuer's 2020 annual meeting of stockholders.
Billionaire Hedge Funds
